Full-Time

Senior Compliance Officer

Global R&D and Tech Ops

Posted on 6/6/2026

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

Compensation Overview

$230.4k - $345.6k/yr

+ Bonus + Equity Grants

Pennsylvania, USA + 1 more

More locations: California, USA

Remote

Must travel for business as needed.

Category
Operations & Logistics (1)
Required Skills
Risk Management
Requirements
  • 8+ years of relevant compliance experience
  • Experience supporting the R&D organization of a global pharmaceutical company for at least 2 years
  • Solid judgment and business acumen with understanding of R&D and Tech Ops strategies and ability to assess compliance risks and mitigation strategies in that context
  • Solid understanding of laws and regulations governing the pharmaceutical or healthcare industry, particularly in the R&D and Tech Ops area, with experience in supporting global pharmaceutical company operations
  • Experience working in a business environment across multiple functions and geographies, with a high level of responsiveness and a strong customer service orientation
  • Excellent communication skills, both oral and written, able to be enthusiastic, self-motivated, efficient, handle heavy workload, proactively identify short and mid-term business needs to develop strategies and to manage responsibilities independently as well as facilitate teamwork
  • Able to work accurately with an appropriate sense of urgency and function effectively and efficiently in a fast-paced and dynamic environment
  • Strong interpersonal skills, including diplomacy, flexibility and collaboration, and the ability to interface effectively throughout all levels of the organization as well as with external parties, adaptable to various cultures
  • Travel required
Responsibilities
  • Serves as strategic business partner and risk advisor to R&D and Tech Ops departments across all of the various countries and therapeutic areas in which those departments operate, providing regular updates on compliance risk areas, mitigation strategies, and dashboards evidencing compliance program effectiveness
  • Provides compliance advice and support to the R&D and Tech Ops, including identifying, mitigating and managing fraud and abuse and kickback risks associated with clinical trial and other development activities; ethical decision-making in clinical trial protocol, strategy, and design, and trade sanctions related risks
  • Serves as the subject matter expert and coordinates and collaborates with the Senior Compliance Officer, Global Policies, Education, and Investigations to develop global compliance and ethics policies and associated training and education materials to support the R&D and Tech Ops departments
  • Regularly conduct compliance training
  • Serves as the subject matter expert and coordinates and collaborates with the Senior Compliance Officer, Monitoring, Auditing, and Third-Party Risk Management to inform the design and implementation of an effective monitoring and audit program in support of the R&D and Tech Ops departments, with a particular focus on compliance oversight of CRO and other partners
  • Serves as a key member of the Ethics, Compliance, and Privacy lead team, coordinating with other lead team members to advance the department's goals and objectives and to drive consistency in the approach to compliance and ethics across the company
  • Stays informed on new laws, regulations, and industry trends affecting the company and ensures that those new developments are appropriately reflected in the compliance controls for the R&D and Tech Ops departments
  • Coordinates and collaborates with members of the Legal departments supporting the R&D and Tech Ops departments
  • Willingly assists Ethics, Compliance, and Privacy department colleagues with projects and activities in areas outside of his/her primary areas of responsibility as needed to achieve corporate objectives, contribute to a collegial atmosphere and balance workloads

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Simplify Jobs

Simplify's Take

What believers are saying

  • Xywav and Epidiolex continue driving double-digit neuroscience revenue growth.
  • Zepzelca's first-line SCLC uptake expands Jazz's oncology franchise rapidly.
  • Chimerix adds dordaviprone, strengthening the late-stage rare-brain-cancer pipeline.

What critics are saying

  • Oxybate franchise concentration exposes revenue to payer pressure and competitive switching.
  • Epidiolex growth slows if adult and long-term-care adoption disappoints.
  • Oncology upside depends on continued Zepzelca and zanidatamab execution.

What makes Jazz Pharmaceuticals unique

  • Rare-disease focus spans neuroscience and oncology with limited-treatment options.
  • Jazz built growth through acquisitions like GW Pharmaceuticals, Celator, and Chimerix.
  • Dublin incorporation and global footprint support cross-border operations and tax optimization.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Jazz Pharmaceuticals who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Intellectia.AI
Mar 4th, 2026
Day One Biopharmaceuticals shares surge 28% on takeover rumours from Ipsen and Jazz

Day One Biopharmaceuticals shares surged 28% amid acquisition rumours, with Jazz Pharmaceuticals and Ipsen cited as potential acquirers. Eight out of nine analysts rate the stock as "buy" or higher, with an average price target of $22.75 representing over 75% upside. The company reported Q4 2025 revenue of $52.8 million for its drug Ojemda, an 83% year-over-year increase. Full-year 2025 net product revenue reached $155.4 million, up 172%. Despite a net loss of $107.3 million in 2025, Day One projects 2026 US revenue between $225 million and $250 million. The biopharmaceutical firm ended 2025 with $441.1 million in cash and no debt. Retail sentiment on Stocktwits remained "extremely bullish" as speculation about a potential merger intensified.

Yahoo Finance
Feb 28th, 2026
Jazz Pharmaceuticals' CBD drug Epidiolex hits $1B in sales — time to buy the stock?

Jazz Pharmaceuticals' cannabidiol therapy Epidiolex has surpassed $1 billion in annual product sales, achieving blockbuster status. The drug, which treats seizures associated with rare epilepsy syndromes, generated $1.1 billion in 2025, representing approximately a quarter of Jazz's total revenues and marking 9% year-over-year growth. Jazz acquired Epidiolex through its $7.2 billion purchase of GW Pharmaceuticals in 2021. The company has resolved nearly all outstanding generic litigation, extending patent protection into the late 2030s and reducing competitive threats. Management sees significant growth potential in adult patients, particularly within long-term care settings. The company is investing in diagnostic tools and patient-support programmes to expand adoption beyond paediatric use. Jazz's portfolio also includes successful neuroscience and oncology products.

Yahoo Finance
Feb 25th, 2026
Jazz Pharmaceuticals shares jump 13.5% on strong Q4 results with $1.2B revenue

Jazz Pharmaceuticals shares rose 13.5% after reporting fourth-quarter 2025 revenue of $1.2 billion, up 10.1% year-on-year and exceeding analyst estimates. Adjusted earnings of $6.64 per share also beat expectations. The company's operating margin expanded to 21.2% from 17.5% in the prior year, demonstrating improved operational efficiency. However, full-year revenue guidance fell short of consensus estimates. Investors appeared to focus on the strong quarterly performance despite the mixed outlook. The shares reached a new 52-week high of $196.34, bringing year-to-date gains to 13.4%. The stock has experienced significant volatility, with 12 moves greater than 5% over the past year.

Jazz Pharmaceuticals
Jun 23rd, 2025
Jazz Pharmaceuticals and Azur Pharma Combine to Create Jazz Pharmaceuticals plc | Jazz Pharmaceuticals plc

DUBLIN , Jan. 18, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of the business combination of Jazz Pharmaceuticals, Inc. and Azur Pharma plc .  The two companies have combined to create Jazz Pharmaceuticals plc , a specialty biopharmaceutical company

CityBiz
Mar 5th, 2025
Jazz Pharmaceuticals Acquires Chimerix for $935M

Jazz Pharmaceuticals is set to acquire Chimerix for $935 million, paying $8.55 per share in cash. The acquisition, expected to close in Q2 2025, will add Chimerix's lead asset, dordaviprone, to Jazz's portfolio. Dordaviprone is a treatment for H3 K27M-mutant diffuse glioma, a rare brain tumor. The FDA has accepted its NDA for accelerated approval, with a PDUFA date of August 18, 2025. Jazz plans to fund the deal through existing cash and investments.